Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt

Memory Impairment: early-phase trial registry

11 of 21 indexed Memory Impairment trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 11 currently recruiting · #797 of 28,707 conditions by registered trial count

Memory Impairment: 21 US clinical trials tracked, 11 recruiting.

Memory Impairment is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Dartmouth-Hitchcock Medical Center, running 3 of these trials.

Enrollment posture brief

Registry condition memory-impairment

OPEN 11 | RECR 52% | LATE 1 | EARLY 3 | RANK #797 | SPON 3

Nearest open-share peer: End-Stage Kidney Disease (52% recruiting · 21 trials)

Memory Impairment (this)52%Anal Cancer42.9%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Memory Impairment

Memory Impairment lists 11 open slots (52% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Memory Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Memory Impairment is recruiting above its size-band peers.

    11 of 21 indexed trials (52.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Memory Impairment trials is spread across many organizations.

    Dartmouth-Hitchcock Medical Center accounts for 3 of 21 trials (14.3%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Typical Memory Impairment enrolment sits around 125 participants.

    Median target enrolment is 125 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.

  4. Memory Impairment research is mostly interventional.

    17 interventional and 4 observational studies make up this index (81% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31

Open and recent trials

21 total, page 1 of 1

RECRUITING 1,200 participants

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

GAP Innovations, PBC

NCT06584357

RECRUITING NA 360 participants

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

Johns Hopkins University

NCT05663034

RECRUITING NA 216 participants

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

Arizona State University

NCT05877196

RECRUITING NA 178 participants

NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment

University of California, Berkeley

NCT05986604

RECRUITING NA 160 participants

Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)

United States Naval Medical Center, San Diego

NCT06413173

RECRUITING NA 150 participants

Brain Health Virtual Reality Study

University of California, San Diego

NCT06124339

RECRUITING NA 125 participants

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Dartmouth-Hitchcock Medical Center

NCT06930846

RECRUITING NA 125 participants

HOBSCOTCH-MS-Efficacy Trial

Dartmouth-Hitchcock Medical Center

NCT06951919

RECRUITING NA 85 participants

Neurobiological Mechanisms of Aging and Stress on Prospective Navigation

Georgia Institute of Technology

NCT03896529

RECRUITING Phase 2 52 participants

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Johns Hopkins University

NCT04601038

RECRUITING 25 participants

Assessing Cognitive Decline at Home

Stanford University

NCT06704971

ACTIVE NOT RECRUITING 400 participants

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

C2N Diagnostics

NCT06025877

ACTIVE NOT RECRUITING NA 10 participants

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

Dartmouth-Hitchcock Medical Center

NCT06391489

COMPLETED NA 510 participants

Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)

University of Washington

NCT01708304

COMPLETED Phase 3 276 participants

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

Wake Forest University Health Sciences

NCT02822573

COMPLETED NA 71 participants

Exercise for Memory Rehabilitation in Epilepsy

University of Alabama at Birmingham

NCT04959019

COMPLETED NA 69 participants

Noninvasive Brain Stimulation for Mild Cognitive Impairment

Palo Alto Veterans Institute for Research

NCT03331796

COMPLETED 22 participants

Mental Ability Challenge Study in Adults With and Without HIV

Vanderbilt University Medical Center

NCT03244488

COMPLETED Early Phase 1 20 participants

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

AstraZeneca

NCT00985933

COMPLETED Phase 2 20 participants

Effect of Insulin Sensitizer Metformin on AD Biomarkers

University of Pennsylvania

NCT01965756

COMPLETED NA 14 participants

Our Care Wishes - Dementia

University of Pennsylvania

NCT05033262

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Memory Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Our Memory Care Wishes Other
1 trials
Placebo rTMS (Inactive) Device
1 trials
Active rTMS (Bilateral LPC) Device
1 trials
Active rTMS (Bilateral DLPFC) Device
1 trials
Donepezil 5 mg Drug
1 trials
Mecamylamine Pill Drug
1 trials
Scopolamine Injectable Product Drug
1 trials

US sites by state

Facility locations filed on Memory Impairment trials. A trial with sites in several states counts in each.

California 7 trials
Pennsylvania 3 trials
New Hampshire 3 trials
Washington 2 trials
Michigan 2 trials
Maryland 2 trials
Illinois 2 trials
Florida 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Memory Impairment page

21 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Memory Impairment condition card totals 21 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.